Operational and financial update for Singular Health Group Limited (ASX: $SHG)

Singular Health Group Limited (ASX: $SHG) has reported significant achievements for the quarter ending 31st March 2024. The company secured two major enterprise purchase orders through its United States Master Distributor, CG1 Solutions. The first order, received from TechWorks4Good in Florida, was for 5,000 3Dicom Patient licenses, while the second order came from Roseman University of Health Sciences in Las Vegas, Nevada. These orders mark a breakthrough for Singular Health's commercialization efforts in the United States.

Executive commentary on recent achievements and strategic developments

The successful procurement of the enterprise purchase orders from TechWorks4Good and Roseman University of Health Sciences in the United States represents a significant milestone for Singular Health. These orders not only demonstrate the growing demand for our 3Dicom licenses but also validate our strategic approach to the US market. We are pleased with the retention of ISO13485 and Medical Device Single Audit Program Certification, which enables us to continue marketing our diagnostic MD software in the USA. The strategic capital raise, along with the investment from Craig Sellars, provides us with the necessary resources to further accelerate our commercialization efforts and capitalize on the positive momentum in the United States.

Summary of operational and financial update with future outlook

Singular Health Group Limited (ASX: $SHG) has achieved significant milestones in the quarter ended 31st March 2024, including the procurement of major enterprise purchase orders in the United States and the retention of key regulatory clearances. The company's strategic capital raise and investment from renowned US technologist Craig Sellars position it well to drive its commercialization efforts and capitalize on the growing demand for its 3Dicom licenses. With a robust cash balance and ongoing strategic initiatives, Singular Health is poised to continue its expansion and solidify its position in the medical technology sector.